Take a PSMA journey with Telix at EAU22
24 June 2022 – Take a journey with Telix at EAU 2022 to discover how PSMA diagnostics are changing the landscape for prostate cancer care
As a specialist in urology, Telix is delighted to invite you onboard the PSMA train. Our symposium, taking place during the EAU Congress 2022, will be an opportunity to ensure your PSMA knowledge is right on track. It’s an exciting field, and the train is moving fast, so join our expert travelers as they take you on a journey towards the latest developments in prostate cancer imaging and treatment.
Sunday July 3rd, 2022 at 17:45pm CET – don’t miss out!
RAI Amsterdam Venue, Auditorium 2
Take a virtual journey by joining the live-stream via the Congress Virtual Platform.
Prof Stefano Fanti: What is PSMA all about? 20 min
Prof Jochen Walz: When does PSMA help me? 20 min
Dr Alicia Morgans: The future of prostate cancer management 20 min
Patient cases discussion and roundtable 30 min
Dr Alicia Morgans (Chair and Speaker)
Alicia Morgans is a Genitourinary Medical Oncologist and the Medical Director of the Survivorship Program at the Dana-Farber Cancer Institute. A clinician and investigator, she has expertise in clinical trials and patient-reported outcome measures, as well as incorporating patient preferences and beliefs into clinical decision making. Her research has investigated complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications. Her work has been funded by grants from the Prostate Cancer Foundation and the Department of Defense. She is a member of the advanced and localized prostate cancer treatment guidelines committee of the American Urologic Association and is a member of the cardio-oncology committee of the American Heart Association. Since 2016, she has been President of the Medical Advisory Board for ZERO, a non-profit organization dedicated to supporting education and research funding for prostate cancer research.
Prof Jochen Waltz (Speaker)
Jochen Christoph Walz is a Professor in Urology and Head of the Department of Urology at the Institut Paoli-Calmettes Cancer Centre in Marseille, France. He attended the Medical School of the University of Mainz, Germany and, following his dissertation, he completed his residency in Urology at the Universities of Marseille, France and Hamburg, Germany. He has been a board-certified urologist since 2005. He became a research fellow at the Cancer Prognostics and Health Outcomes Unit at the University of Montreal, Canada in 2006/7 and received his “Habilitation” in 2008 in Urology at the University of Hamburg, Germany. From 2009 to 2017 he was chairman of the EAU Section of Urological Imaging. He specializes in uro-oncology and urological imaging. His main areas of research are imaging in urology, prostate cancer (imaging and diagnosis), prediction tools, life expectancy, surgical treatment, and minimal invasive surgery. Dr. Walz is Co-Editor-in-Chief of European Urology Open Science.
Prof Stefano Fanti (Speaker)
Stefano Fanti was born in Bologna, Italy, where he completed all of his studies and ultimately graduated from the University of Bologna. He began working in conventional nuclear medicine in the 1990s, becoming involved in the PET Unit project at S. Orsola Policlinic Hospital, first participating in site planning, then appointed as medical director in 2002. Last year the PET Unit carried out more than 14,000 exams, making it one of the most active in Europe – it is particularly known for nonFDG scans, in both clinical routine and research areas. At present he is employed full-time in nuclear medicine as Full Professor of Diagnostic Imaging and Director of the Nuclear Medicine Division and PET Unit at the S. Orsola Policlinic Hospital. He is the author of more than 1000 papers, including 450 full articles published in peer-reviewed international journals (more than 18m000 citations with an H-index of 73 on Google Scholar and 60 on Scopus), dozens of books and book chapters. He has been an invited lecturer at more than 200 national and international meetings.
We look forward to seeing you on board!
Return to our home page